{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric%2FGastroesophageal+Junction+Adenocarcinoma&page=2", "query": { "condition": "Gastric/Gastroesophageal Junction Adenocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric%2FGastroesophageal+Junction+Adenocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T03:12:42.424Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04007744", "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Urothelial Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sonidegib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-02-13", "completion_date": "2027-07-02", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04007744" }, { "nct_id": "NCT07392892", "title": "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma", "Metastatic Gastric Cancer", "Gastroesophageal Junction Cancer", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "PF-08634404", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2026-04-28", "completion_date": "2032-07-21", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 56, "location_summary": "Aurora, Colorado • Boulder, Colorado • Centennial, Colorado + 47 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07392892" }, { "nct_id": "NCT05128487", "title": "A Study of NDI 1150-101 in Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Renal Cell Carcinoma (Kidney Cancer)", "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "NDI-101150", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nimbus Saturn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-11-05", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ocala", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05128487" }, { "nct_id": "NCT05111626", "title": "Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 515, "start_date": "2022-03-14", "completion_date": "2027-01-29", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Cerritos, California • Downey, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05111626" }, { "nct_id": "NCT02485834", "title": "FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Gastric Adenocarcinoma", "Gastric Cancer" ], "interventions": [ { "name": "FDG-PET", "type": "PROCEDURE" }, { "name": "surgery", "type": "PROCEDURE" }, { "name": "5-FU", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "3D-CRT", "type": "RADIATION" }, { "name": "IMRT", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-11-12", "completion_date": "2018-08-01", "has_results": true, "last_update_posted_date": "2025-01-20", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 71, "location_summary": "Los Angeles, California • St. Helena, California • Newark, Delaware + 47 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "St. Helena", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02485834" }, { "nct_id": "NCT02283359", "title": "Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-12", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-01-15", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02283359" }, { "nct_id": "NCT00848783", "title": "Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2008-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-01-08", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00848783" }, { "nct_id": "NCT06605404", "title": "Pan-tumor MRD Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Esophageal Cancer", "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma", "Melanoma (Skin Cancer)", "NSCLC (Non-small Cell Lung Cancer)", "Pancreatic (Exocrine Only)", "Mix of Solid Tumors (MOST)" ], "interventions": [ { "name": "blood and tissue samples", "type": "DIAGNOSTIC_TEST" }, { "name": "blood and tissue samples", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Paradigm Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1350, "start_date": "2025-01-08", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 2, "location_summary": "San Diego, California • Maumee, Ohio", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Maumee", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06605404" }, { "nct_id": "NCT04660760", "title": "Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2021-06-16", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2024-04-01", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660760" }, { "nct_id": "NCT00022139", "title": "Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2002-01", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-05-22T03:12:42.424Z", "location_count": 35, "location_summary": "Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 22 more", "locations": [ { "city": "Chanute", "state": "Kansas" }, { "city": "Dodge City", "state": "Kansas" }, { "city": "El Dorado", "state": "Kansas" }, { "city": "Kingman", "state": "Kansas" }, { "city": "Liberal", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022139" } ] }